I-FDA iyayivuma i-ibutinib yonyango lwesifo esingapheliyo se-graft-versus-host (cGVHD) ebantwaneni

Ngomhla wama-24 ku-Agasti, ngo-2022, i-US Food and Drug Administration (FDA) yavuma i-ibutinib yonyango lwezigulane zabantwana ezingaphezulu konyaka omnye ezinesifo esinganyangekiyo se-graft-versus-host (cGVHD) ezifumana unyango lwe-systemic emva kokungaphumeleli konyango lwe-1- okanye lwe-multi-line. Isalathisi esivunyiweyo ikakhulu sesezigulane zabantwana, kunye nezinga lokuphendula lilonke le-60% kwiveki yama-25, kwaye iindlela zamayeza ziquka ii-capsules, iipilisi kunye ne-oral suspensions.

I-Ibrutinib, i-BTK inhibitor eyaphuhliswa yi-Pharmacyclics/Johnson & Johnson, yi-kinase inhibitor eyayivunyiwe ngaphambili kunyango lwe-chronic lymphocytic leukemia kunye ne-cell lymphoma kunye nezinye izifo.

I-Suntech igxile ekuphuhlisweni nasekuvelisweni kwe-pharmaceutical intermediates kunye ne-APIs kusetyenziswa iteknoloji eluhlaza. Okwangoku, inkampani yethu iphuhlise iimveliso ezintathu eziphakathi ze-ibrutinib kuquka i-C AS: 143900-44-1, i-C AS: 330792-70-6, i-C AS: 330786-24-8, zonke ezithengiswa kwimveliso yeefektri ze-GMP. Phakathi kwazo, i-pharmaceutical ye-C AS: 143900-44-1 iveliswa yitekhnoloji ye-chemical-enzymatic, enezibonelelo zokhuseleko lokusingqongileyo oluluhlaza, ixabiso eliphantsi kunye nomgangatho ophezulu. Wamkelekile ukubonisana nokusebenzisana!